Date	e:2023.11.15_			
	nuscript Title:Non-targeted I nocarcinoma	Metabolomics Analysis of I	DO Inhibitor Treatment in a Mouse Model of Early-stage Lu	ng
		TCR-23-1236		
iviai	idscript number (ii known).	TCN 23 1230		
relate part to trelate	ted to the content of your miles whose interests may be ansparency and does not not interest, it	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. I is preferable that you do	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so. s/activities/interests as they relate to the current	
	uscript only.	o the admor s relationship	sydetivities, interests as they relate to the <u>earrent</u>	
to the	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare a tion is not mentioned in th port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript. In this manuscript without time limit. For all other items,	
		Name all entities with	Specifications/Comments	
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Canaulking for	V .:		
4	Consulting fees	XNone		

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending meetings and/or travel	X None		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid	V Nove		
11	Stock or stock options	X None		
12	Descipt of anytings out	V N		
12	Receipt of equipment, materials, drugs, medical	X None		
	writing, gifts or other			
	services			
13	Other financial or non-	X None		
	financial interests			
ы.				

Please summarize the above conflict of interest in the following box:

The author has no conflic	cts of interest to declare.		

Please place an "X" next to the following statement to indicate your agreement:

2023.11.15

Date:__

You	r Name:Jiayang Chen_			_
Mar	nuscript Title:Non-targeted I	Metabolomics Analysis of I	DO Inhibitor Treatment in a Mouse Model of Early-sta	ge Lung
Ade	nocarcinoma			
Mar	nuscript number (if known):	TCR-23-1236		
related to the man to the med	ted to the content of your mies whose interests may be cansparency and does not not itionship/activity/interest, it following questions apply to suscript only. author's relationships/activity e epidemiology of hyperter lication, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertai Il relationships with manufacturers of antihypertensiv	re
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	_ X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
		61 6	

Please summarize the above conflict of interest in the following box:

The aut	The author has no conflicts of interest to declare.			

Please place an "X" next to the following statement to indicate your agreement:

2023.11.15

Date:___

You	r Name:Chaoyang Pen	ng		
Maı	nuscript Title:Non-targeted I	Metabolomics Analysis of	IDO Inhibitor Treatment in a Mouse Model of Early-stag	ge Lung
Ade	nocarcinoma			
Maı	nuscript number (if known):	TCR-23-1236		
rela part to to to rela The man	ted to the content of your matters whose interests may be ransparency and does not not tionship/activity/interest, it following questions apply to muscript only. author's relationships/activity he epidemiology of hypertendication, even if that medication.	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. is preferable that you do the author's relationship rities/interests should be g nsion, you should declare tion is not mentioned in t	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertainally relationships with manufacturers of antihypertensive	e
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: pas	t 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None		
3	Royalties or licenses	X None		
4	Consulting fees	X None		
•	2554111115 1223			

5	Payment or honoraria for lectures, presentations,	XNone				
	speakers bureaus, manuscript writing or					
	educational events					
6	Payment for expert	XNone				
	testimony					
7	Support for attending	V Nege				
,	meetings and/or travel	_XNone				
8	Patents planned, issued or pending	X_None				
	pending					
9	Participation on a Data	XNone				
	Safety Monitoring Board or					
	Advisory Board					
10	Leadership or fiduciary role in other board, society,	XNone				
	committee or advocacy group, paid or unpaid					
11	Stock or stock options	X None				
12	Receipt of equipment,	XNone				
	materials, drugs, medical writing, gifts or other					
	services					
13	Other financial or non-	XNone				
	financial interests					
Ple	Please summarize the above conflict of interest in the following box:					
Г	The continue of the Continue o					
	The author has no conflicts of interest to declare.					

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023.11.15		
Your Name:	Liang Mo		
Manuscript Tit	le: Non-targeted Me	tabolomics Analysis of IDO Inhibitor Treatment in a Mouse Model of Early-stag	ge Lung
Adenocarcinon	ma		
Manuscript nu	mber (if known):	TCR-23-1236	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	Project of Hunan Provincial Health Commission (No. 20200247)	To me
	medical writing, article processing charges, etc.) No time limit for this item.	Hunan Province Clinical Medical Technology Innovation Guidance Project (No. 2020SK51825)	To me
		Hunan Provincial Natural Science Foundation (No. 2021JJ30618)	To me
		Hunan Province Degree and Graduate Teaching Reform Research Project (No. 2022JGYB172)	To me
		Ministry of Education's Industry School Cooperation Collaborative Education Project (No. 220601867221601)	To me

2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone
3	Royalties or licenses	XNone
4	Consulting fees	XNone
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_X_None
13	Other financial or non- financial interests	XNone

Please summarize the above conflict of interest in the following box:

Liang Mo received funding from the Project of Hunan Provincial Health Commission (No. 20200247), the Hunan Province Clinical Medical Technology Innovation Guidance Project (No. 2020SK51825), the Hunan Provincial Natural Science Foundation (No. 2021JJ30618), the Hunan Province Degree and Graduate Teaching Reform Research Project (No. 2022JGYB172), and the Ministry of Education's Industry School Cooperation Collaborative Education Project (No. 220601867221601).

Please place an "X" next to the following statement to indicate your agreement: